Letter to editor regarding "bone modifying agents in breast cancer patients as adjuvant therapy and prevention of cancer treatment-induced bone loss (CTIBL): Evaluation of risk of medication-related osteonecrosis of the jaw (MRONJ)"

Support Care Cancer. 2024 Oct 1;32(10):698. doi: 10.1007/s00520-024-08891-8.

Giuseppina Campisi^{1

2}, Alberto Bedogni^{3

4}, Giorgia Saia⁴, Martina Coppini^{2

5}, Rodolfo Mauceri^{6

7}, Vittorio Fusco^{8

9}

¹ University of Palermo, Palermo, Italy.
² Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, 90127, Palermo (PA), Italy.
³ Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padua, 35121, Padua (PD), Italy.
⁴ Department of Neuroscience, University of Padova, 35121, Padua (PD), Italy.
⁵ Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, Italy.
⁶ Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, 90127, Palermo (PA), Italy. [email protected].
⁷ Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, Italy. [email protected].
⁸ Department of Medicine, Oncology Unit, "SS Antonio E Biagio E C. Arrigo" Hospital, 15121, Alessandria, Italy.
⁹ DAIRI - Department of Integration, Research and Innovation, Translational Medicine Unit, "SS Antonio E Biagio E C. Arrigo" Hospital, Alessandria, Italy.

No abstract available

Publication types